A phase iia randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade RAD5 HIV-1 vaccine boost in healthy adults (HVTN204)

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Churchyard, Gavin J ^a,b   Morgan, Cecilia ^c   Adams, Elizabeth ^d   Hural, John ^c   Graham, Barney S ^d   Moodie, Zoe ^c   Grove, Doug ^c   Gray, Glenda ^e   Bekker, Linda Gail ^f   McElrath, M Juliana ^c   Tomaras, Georgia D ^g   Goepfert, Paul ^h   Kalams, Spyros ⁱ   Baden, Lindsey R ^j   Lally, Michelle ^k   Dolin, Raphael ^l   Blattner, William ^m   Kalichman, Artur ⁿ   Figueroa, J Peter ^o   Pape, Jean ^p   Schechter, Mauro ^q   Defawe, Olivier ^c   de Rosa, Stephen C ^c   Montefiori, David C ^r   Nabel, Gary J ^d   Corey, Lawrence ^c   Keefer, Michael C ^s   more..

^a AURUM INSTITUTE   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Fred Hutchinson Cancer Research Center   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k BROWN UNIVERSITY   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^m UNIVERSITY OF MARYLAND   (United States)

ⁿ Centro de Referencia e Treinamento em DST/AIDS   (Brazil)

^o Epidemiology Research and Training Unit (ERTU)   (Jamaica)

^p Department of Adolescent Medicine   (Haïti)

^q FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^r DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IMMUNOGLOBULIN G; NEF PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; POL PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ABDOMINAL PAIN; ADENOVIRUS 5; ADULT; ANEMIA; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTHRALGIA; ARTICLE; BODY TEMPERATURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE; DERMATITIS; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; EPITOPE MAPPING; EXCORIATION; FATIGUE; FEMALE; FURUNCULOSIS; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; LYMPHADENOPATHY; MALAISE; MALE; MENORRHAGIA; MYALGIA; NEEDLE; NEUTROPENIA; NEUTROPHIL COUNT; OTITIS MEDIA; PATIENT MONITORING; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RHINOPHARYNGITIS; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SINUSITIS; SKIN ABRASION; SKIN ABSCESS; SPONTANEOUS ABORTION; STOMACH DISCOMFORT; SYRINGE; T LYMPHOCYTE; TOOTH ABSCESS; TOOTH PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VIRUS INFECTION; VIRUS RECOMBINANT; VOMITING; WEIGHT REDUCTION; ADENOVIRUS; ADOLESCENT; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOVIRIDAE; ADOLESCENT; ADULT; AIDS VACCINES; ANEMIA; ANTIBODIES, VIRAL; COHORT STUDIES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINES, DNA; YOUNG ADULT;

EID: 79961048088     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021225     Document Type: Article

References (32)

1. Joint United Nations Programme on HIV/AIDS (2009) 2009 AIDS epidemic update. Available: http://data.unaids.org/pub/Report/2009/jc1700_epi_update_2009_en.pdf.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-20.
3. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58: 19-42.
4. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649.
5. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, et al. (2007) Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25: 4085-4092.
6. Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, et al. (2007) Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 25: 7737-7742.
7. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194: 1650-1660.
8. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, et al. (2010) Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLOS One 5: e9015.
9. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, et al. (2006) Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312: 1530-1533.
10. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, et al. (2006) Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203: 1533-1541.
11. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, et al. (2010) A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 201: 600-607.
12. Jaoko W, Karita E, Kayitenkore K, Omosa G, Allen S, et al. (2010) Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLOS One PLoS One 5: e12873.
13. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
14. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, et al. (2006) Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24: 6893-6904.
15. Bull M, Lee D, Stucky J, Chiu YL, Rubin A, et al. (2007) Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 322: 57-69.
16. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323: 39-54.
17. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, et al. (2007) Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 25: 510-518.
18. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
19. Mascola JR, Souza D, Gilbert P, Hahn BH, Haigwood NL, et al. (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79: 10103-10107.
20. Polonis VR, Brown BK, Rosa BA, Zolla-Pazner S, Dimitrov DS, et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315-320.
21. Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, et al. (2010) Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 59: 1489-1501.
22. Agresti A, Coull BA, (1998) Approximate is better than exact for interval estimation of binomial parameters. Am Stat 52: 199-226.
23. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
24. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
25. Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, et al. (2011) An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 203: 765-772.
26. Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, et al. (2011) Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 17: 366-371.
27. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, et al. (2005) Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79: 2956-2963.
28. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957.
29. Cheng C, Gall JG, Nason M, King CR, Koup RA, et al. (2010) Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84: 630-638.
30. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, et al. (2010) Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol 84: 4998-5006.
31. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, et al. (2010) Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 201: 720-729.
32. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, et al. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 4;3: 81ra36.